US challenges 'bogus' patents on Ozempic and other drugs in effort to spur competition
WASHINGTON (AP) — Federal regulators are challenging patents on 20 brand name drugs, including the blockbuster weight-loss injection Ozempic, in the latest action by the Biden administration targeting industry practices that drive up pharmaceutical prices.
The Federal Trade Commission on Tuesday sent warning letters to 10 drugmakers, taking issue with patents on popular drugs for weight loss, diabetes, asthma and other reparatory conditions. The letters allege that certain patents filed by Novo Nordisk, GlaxoSmithKline, AstraZeneca and seven other companies are inaccurate or misleading.
Brand-name drugmakers use patents to protect their medicines and stave off cheaper, generic medicines. Most blockbuster drugs are protected by dozens of patents covering various ingredients, manufacturing processes and intellectual property. Generic drugmakers can only launch their own cheaper versions if the patents have expired or are successfully challenged in court.
Related articles
'The Apprentice,' about a young Donald Trump, premieres in Cannes
CANNES, France (AP) — While Donald Trump’s hush money trial entered its sixth week in New York, an o2024-05-21- Contact Us HomeNewsHighlightACWF NewsSocietyWom2024-05-21
CPC Central Committee Holds Consultative Meeting on Reform Plan of Party, State Institutions
Contact Us HomeNewsHighlightACWF NewsSocietyWom2024-05-21Residents and tourists seized the tail of ski season in Urumqi to enjoy snow fun
Beijing, March18 (Youth.cn) -On March 17th, 2024, in Urumqi,at the Silk Road Mountain Resort, ski en2024-05-21Kate Hudson hits the stage to debut songs from her new album Glorious at star
Kate Hudson looked like a pro as she performed songs from her new album Glorious for the first time.2024-05-21AI will continue to make waves in 2024
MA XUEJING/CHINA DAILYIn the fast-changing global economic landscape in 2023, artificial intelligenc2024-05-21
atest comment